COVID-19 vaccine: adverse events in Spain by manufacturer

As of December 31, 2022, a total of 44,280 adverse events were reported in Spain after vaccination with Comirnaty Original, while 770 cases corresponded to the Bivalent dose. As of that date, the vaccine developed by Pfizer/BioNTech was the most used against COVID-19 within the country, with over 67.2 million doses administered of the original version and more than seven million of the bivalent vaccine. The most common adverse events recorded with the Pfizer/BioNTech vaccine were pyrexia (fever), headache, and myalgia.

Number of adverse events reported after receiving the coronavirus (COVID-19) vaccine in Spain as of December 31, 2022, by manufacturer

Characteristic	Number of cases
Pfizer/BioNTech (Original)	44,280
Moderna (Original)	20,193
Oxford/AstraZeneca*	12,503
Janssen*	1,451
Pfizer-BioNTech Bivalent (Original/ Omicron BA.4-5)	770
Moderna Bivalent (Original/ Omicron BA.1)	47
Novavax	3

Loading statistic...

Download

Source

Show detailed source information?

Already a member?

Source

Use Ask Statista Research Service

Release date

January 2023

More information

Region

Spain

Survey time period

as of December 31, 2022

Supplementary notes

Includes any kind of adverse event notified after receiving the coronavirus (COVID-19) vaccine. Adverse events are not to be interpreted as induced by the vaccine until a casual relationship is confirmed.

As of December 31, 2022, the total number of doses administered in Spain was as follows:

Pfizer/BioNTech: 67,263,416 doses
Pfizer/BioNTech Bivalent: 7,918,291 doses
Moderna: 24,139,935 doses
Moderna Bivalent: 195,281 doses
Novavax: 648 doses

The total administered doses for Oxford/AstraZeneca and Janssen were not reported as of that date.

*Based on previous reporting,

Citation formats